Mr. Schallenberger will step into his role Jan. 16, according to a news release. He has more than 12 years of experience in the orthobiologics industry and previously worked at Surgenex.
“In this newly created role, Mark will drive the modernization of our production, lead the optimization of our processes and operations, and support the diversification and development of new product lines,” Sean Browne, president and CEO of Xtant Medical said in the release. “We look forward to Mark’s contributions to our key growth pillars.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.